Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Daraxonrasib nearly doubles survival in previously treated metastatic pancreatic cancer

ASCO 2026

29 May - 2 Jun 2026

Published: 31 May 2026

Views: 2176

Rating:

Save

Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA

Dr Brian Wolpin talks to ecancer at ASCO 2026 about results from the phase 3 RASolute 302 trial evaluating daraxonrasib as second-line treatment for metastatic pancreatic ductal adenocarcinoma.

The RAS(ON) multi-selective inhibitor nearly doubled overall survival and improved progression-free survival and response rates compared with chemotherapy, with fewer serious side effects.

Dr Wolpin notes that daraxonrasib has potential as anew standard of care in the second-line setting for metastatic pancreatic cancer.

Read the news story here.

Related Videos

Abemaciclib shows benefit in dedifferentiated liposarcoma

Dr Mark Dickson - Memorial Sloan Kettering Cancer Center, New York, USA

Abemaciclib shows benefit in dedifferentiated liposarcoma ( Dr Mark Dickson - Memorial Sloan Kettering Cancer Center, New York, USA )

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer

Dr Jonathan W. Goldman - University of California Los Angeles, Los Angeles, USA

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer ( Dr Jonathan W. Goldman - University of California Los Angeles, Los Angeles, USA )

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

Denikitug shows immune activation and early anti-tumour activity in advanced...

Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA

Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour ( Dr Bruno Bockorny - Beth Israel Deaconess Medical Center, Boston, USA )

Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI...

Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA

Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI-resistant solid tumours ( Dr Timothy Yap - UT MD Anderson Cancer Center, Houston, USA )

Oral molecular glue degrader with or without spartalizumab shows immune...

Dr Elena Garralda - Vall d’Hebron University Hospital, Barcelona, Spain

Oral molecular glue degrader with or without spartalizumab shows immune activation and tumour control in solid tumours ( Dr Elena Garralda - Vall d’Hebron University Hospital, Barcelona, Spain )

ctDNA positivity predicts poor response and recurrence risk in triple-negative...

Dr Priya Rastogi - NSABP Foundation & University of Pittsburgh School of...

ctDNA positivity predicts poor response and recurrence risk in triple-negative breast cancer ( Dr Priya Rastogi - NSABP Foundation & University of Pittsburgh School of Medicine, Pittsburgh, USA )

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas

Dr Rohit Thummalapalli - Memorial Sloan Kettering Cancer Center, New York, USA

ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas ( Dr Rohit Thummalapalli - Memorial Sloan Kettering Cancer Center, New York, USA )

The potential of T-cell engagers in SCLC treatment

Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain

The potential of T-cell engagers in SCLC treatment ( Dr Luis Paz-Ares - 12 de Octubre University Hospital, Madrid, Spain )

More from ecancer